AbbVie Inc. buy BMO Capital Markets
Start price
05.02.24
/
50%
€156.90
Target price
05.02.25
€181.45
Performance (%)
-3.52%
Price
02.05.24
€149.92
Summary
This prediction is currently active. With a performance of -3.52%, the BUY prediction for AbbVie Inc. by BMO_Capital_Markets is down slightly. A total of €1.46 was paid as dividends for this prediction. This prediction currently runs until 05.02.25. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| AbbVie Inc. | -2.844% | -2.844% |
| iShares Core DAX® | -0.992% | -3.231% |
| iShares Nasdaq 100 | -0.225% | -3.339% |
| iShares Nikkei 225® | -0.736% | -7.859% |
| iShares S&P 500 | -0.509% | -2.979% |
Comments by BMO_Capital_Markets for this prediction
In the thread AbbVie Inc. diskutieren
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at BMO Capital Markets from $187.00 to $195.00. They now have an "outperform" rating on the stock.
Ratings data for ABBV provided by MarketBeat